PCN42 COSTS OF MANAGING ADVERSE EVENTS OF FIRST-LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA IN MEXICO- BEVACIZUMAB IN COMBINATION WITH INTERFERON-ALPHA-2A COMPARED WITH SUNITINIB
Abstract
Authors
F Carlos J Ramirez A Aguirre